

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

#### OMB APPROVAL OMB 3235-Number: 0104 Estimated average burden hours per response... 0.5

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)						
1. Name and Address of Reporting Person *2. Date of Eve Statement (Month/Day/Y) 07/28/2017			3. Issuer Name <b>and</b> Ticker or Trading Symbol Sevion Therapeutics, Inc. [SVON]			
(Last) (First) (Middle) 4400 BISCAYNE BLVD.	07/28/2017		4. Relationship of Report Person(s) to Issuer		-	5. If Amendment, Date Original Filed(Month/Day/Year)
(Street) MIAMI, FL 33137			(Check all applicable) DirectorOfficer (giveOther (specify title below)below)		wner	6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person
(City) (State) (Zip)	Table I - Non-Derivative Securities Beneficially Owned					
1.Title of Security (Instr. 4)	Ве	Amount of eneficially C nstr. 4)		3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	Owner	•
Common Stock	10	10,517,016		D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		or Exercise Price of	Ownership Form of Derivative	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Security: Direct (D) or Indirect (I) (Instr. 5)	
0% Series C Convertible Perferred (1)	<u>(2)</u>	<u>(2)</u>	Common Stock	1,250,007	\$ 0.4	D	
Warrant (Right to Buy) $(3)$	05/16/2014	05/16/2019	Common Stock	6,741	\$ 2	D	
Warrant (Right to Buy) $(1)$	07/27/2015	01/27/2018	Common Stock	333,333	\$ 1.5	D	
Convertible Promissory Note <sup>(1)</sup>	02/24/2017	08/24/2017	Common Stock	2,500,000	\$ 0.1	D	
Convertible Promissory Note <sup>(1)</sup>	11/10/2016	11/10/2017	Common Stock	1,500,000	\$ 0.1	D	

## **Reporting Owners**

Reporting Owner Name / Address	Relationships						
Reporting Owner Ivanie / Address	Director	10% Owner	Officer	Other			
Opko Health, Inc.							

4400 BISCAYNE BLVD.	Х	
MIAMI, FL 33137		

### Signatures

Adam Logal, Chief Financial Officer 08/04/2017

\*\*Signature of Reporting Person

08/04/201 Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The derivative security was previously subject to a "blocker" pursuant to which the reporting person was unable to convert the derivative security to the extent such conversion would result in the reporting person owning more than 4.99%.
- (2) The convertible preferred stock is convertible at any time at the holder's option and has no expiration date.
- (3) The derivative security was previously subject to a "blocker" pursuant to which the reporting person was unable to convert the derivative security to the extent such conversion would result in the reporting person owning more than 9.99%.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.